Therapeutic interventions initiated in patients with active AD and based on the hypothesis of amyloid and Tau hyperphosphorylation resulted in very poor outcomes, as did therapies with antioxidant, anti-inflammatory and neuroprotective agents. Here, MAPT is linked to Alzheimer disease.